Skip to main content
SpringerLink
Log in

EGFR-mutiertes nichtkleinzelliges Lungenkarzinom

Bessere Behandlungsmöglichkeit nach Osimertinib-Versagen

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Park K et al. .J Clin Oncol. 2021;39(30):3391-402

  2. Passaro et al. Ann Oncol. 2024;35(1):77-90

  3. Cho BC et al. ESMO Congress 2023, LBA14; Ann Oncol. 2023; https://doi.org/10.1016/j.annonc.2023.10.062

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Lungenklinik Gauting, Robert-Koch-Allee 2, 82131, Gauting, Deutschland

    Daniel Hamberger Dr. med. univ.

Authors
  1. Daniel Hamberger Dr. med. univ.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamberger, D. Bessere Behandlungsmöglichkeit nach Osimertinib-Versagen. InFo Hämatol Onkol 27, 26–27 (2024). https://doi.org/10.1007/s15004-024-0575-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-024-0575-4

Search

Navigation